Abstract：ObjectiveTo investigate the clinical effect of autologous hematopotietic stem cell transplantation(APBSCT) for patients with multiple myeloma (MM).Methods20 cases of MM in our hospital from February 2008 to December 2016 were given the chemotherapy combined with granulocyte colony stimulating factor(G-CSF)for mobilizing autologous hematopotietic stem cells.APBSCT was performed after pretreatment of oral melphalan,and the effect were evaluated.Results20 cases were succeeded in transplantation and there was no transplantation-related death.Therapeutic effect of patients after APBSCT was obviously better than that before transplantation(P<0.05).ConclusionAPBSCT is a safe and efficient therapy for patients with MM,and has the important significance to improving therapeutic effects and prognosis of patients with MM.
Siegel RL，Miller KD，Jemal A.Cancer statistics[J].CA Cancer J Clin，2015，65（1）：5-29.
[3]
Anderson KC，Alsina M，Bensinger W，et al.Multiple myeloma Clinical practice guidelines in oncology[J].J Natl compr Canc Netw，2011，9（10）：1146-1183.
[6]
Martinez-Lopez J，Blade J，Mateos MV，et al.Long-termprognostic significance of response in multiple myeloma after stem cell transplantion[J].Blood，2011，118（3）：529-534.
[7]
Brenner H，Gondos A，Pulte D.Recent major improvement in long-term survival of younger patients with multiple myeloma[J].Blood，2008，111（5）：2521-2526.
[8]
Pulte D，Redaniel MT，Brenner H，et al.Recent improvement in survival of patients with multiple myeloma：variation by ethnicity[J].Leuk Lymph，2014，55（5）：1083-1089.
[10]
Barlogie B，Mitchell A，van Rhee F，et al.Curing myeloma at last：defining criteria and providing the evidence[J]. Blood，2014，124（20）：3043-3051.
[11]
Hahn T，Wingard JR，Anderson KC，et al.The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma：an evidence-based review[J].Biol Blood Marrow Transplant，2003，9（1）：4-37.
[12]
Artinez-Lopez J，Blade J，Mateos MV，et al.Long-term prognostic significance of response in multiple myeloma after stem cell transplantation[J].Blood，2011，118（3）：529-534.
[13]
Cook G，Ashcroft AJ，Cairns DA，et al.The efect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma （final results from BSBMT/UKMF Myeloma X Relapse [Intensive]）：a randomised，open-label，phase 3 trial[J].Lancet Haematol，2016，3（7）：e340-e351.
[15]
Zhang Q，Bat H，Wang CB，et al．Bortezomib combined withautologousperipheral blood hematopoietic stem celltransplantation for therapy of patients with multiple myelo ma[J]．Zhongguo Shi Yan Xue Ye Xue Za Zhi，2011，19（5）：1234-1236.
[16]
Sonneveld P，Goldschmidt H，Rosinol L，et al.Bortezomibbased versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma：a meta-analysis of phaseⅢ randomized，controlled trials[J].J Clin Oncol，2013，31（26）：3279-3287.
[17]
Cornell RF，D'Souza A，Kassim AA，et al.Maintenance versus induction therapy choice on outcomes after autologous transplantation for multiple myeloma[J].Biol Blood Marrow Transplant，2017，23（2）：269-277.
[18]
Hahnast C，Von Lilienfeldtoal M，Van HP，et al.Improved progression-free survival and overall survival with thalidomide maintenance therapy in multiple myeloma：a metaanalyis of randomized trials in 2274 patients[J].Haematol Hematology J，2010，95（3）：391.
Schmidt-Hieber M，Blau IW，Trenschel R，et al.Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma[J]. Bone Marrow Transplant，2007，39（7）：389-396.
[21]
Barlogie B，Attal M，Crowley J，et al.Long-term follow-up of autotransplantation trials for multiple myeloma：update of protocols conducted by the Intergroupe Francophone du Myelome，Southwest Oncology Group and the University of Arkansas for Medical Sciences[J].J Clin Oncol，2010，28（7）：1209-1214.
[22]
CohenYC，ZuckermanT，YeshurunM，etal.Efficacyandsafety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma：a retrospective national multi-site cohort study[J].Ann Hematol 2017，96（2）：271-278.
京公网安备 11010502046607号